P.0835 Synergistic effects of lysergic acid diethylamide (LSD) and cannabidiol (CBD)

Inserra, Antonio; Billard, Étienne; Grant, Emily; Markopoulous, A.; Pilegggi, M.; Haque, Minza; Oveisi, A.; Singer, Jorie; Gregorio, Danilo De; Hébert, Terry; Gobbi, Gabriella

doi:10.1016/j.euroneuro.2021.10.694

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional repeating of LSD administration (0.13 mg/kg) for 11 days was able to reverse deficits in active avoidance learning in bulbectomised rats, a model of depression [ 214 ]. Furthermore, cannabidiol (CBD) seems to exert a synergistic effect in combination with LSD on the antidepressant effect in mice, probably due to an allosteric modulation of the 5-HT2A receptor by CBD, which causes a powerful and rapid inhibition of serotonergic and glutamatergic transmission [ 239 ]. An additional potential therapeutic application of LSD concerns its positive effect on social behaviour, which can be applied in the context of mental illnesses characterized by dysfunction in social behaviour, such as autism spectrum disorders (ASD) and social anxiety disorder.…”

Section: Claviceps Purpureamentioning

confidence: 99%

“…In the past, several clinical trials were carried out and from these it emerged that LSD may be a useful pharmacological compound for the treatment of drug dependence, anxiety and mood disorders, especially in treatment-resistant patients [ 222 , 239 , 242 , 243 ]. Furthermore, many clinical studies carried out in the 60s and 70s investigated the possible use of LSD for the treatment of people with ASD and positive evidence emerged.…”

Section: Claviceps Purpureamentioning

confidence: 99%

See 1 more Smart Citation

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Mastinu

Anyanwu

Carone

et al. 2023

IJMS

View full text Add to dashboard Cite

The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics. For several years there has been growing interest among psychotherapists in psilocybin or lysergic acid diethylamide for the treatment of obsessive-compulsive disorder, of depression, or of post-traumatic stress disorder, although results are not always clear and definitive. In fact, the mechanisms of action of psychedelics are not yet fully understood and some molecular aspects have yet to be well defined. Thus, this review aims to summarize the ethnobotanical uses of the best-known psychedelic plants and the pharmacological mechanisms of the main active ingredients they contain. Furthermore, an up-to-date overview of structural and computational studies performed to evaluate the affinity and binding modes to biologically relevant receptors of ibogaine, mescaline, N,N-dimethyltryptamine, psilocin, and lysergic acid diethylamide is presented. Finally, the most recent clinical studies evaluating the efficacy of psychedelic molecules in some psychiatric disorders are discussed and compared with drugs already used in therapy.

show abstract

Section: Claviceps Purpureamentioning

confidence: 99%